Chronic Kidney Disease Trial, Recruiting NCT06750575 Sponsor: UMC Utrecht Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT06750575
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with chronic kidney disease (stage 3–5), meaning their kidneys have been functioning at a reduced level for at least three months
  • People for whom a doctor has decided, as part of their normal care, that starting a water tablet called furosemide is appropriate
  • People who are willing to take part and have signed a consent form agreeing to participate

Who may not be able to join:

  • People who are already taking furosemide
  • People who have a liver disease that causes a build-up of bilirubin (a yellow substance) in the body
  • People who are already receiving any form of kidney replacement therapy, such as peritoneal dialysis or haemodialysis
  • People who have end-stage kidney failure and whose kidneys no longer produce any urine
  • People who are starting other new medications at the same time as furosemide that could interfere with how certain waste products are processed or carried in the blood (confirm with trial site)
  • People who are legally considered unable to make their own decisions

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Karin GF Gerritsen, MD, PhD, UMC Utrecht

Phone: +31-887557375

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
UMC Utrecht
Registry
ClinicalTrials.gov
Start date
10 June 2024
Est. completion
1 July 2025

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Plasma levels of the PBUT indoxyl sulfate; Plasma levels of the PBUT p-cresyl sulfate; Plasma levels of the PBUT indole-3-acetic acid; Plasma levels of the PBUT kynurenic acid; Plasma levels of the PBUT L-kynurenine; Plasma levels of the PBUT hippuric acid; Plasma levels of the PBUT p-cresyl glucuronide

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov